NasdaqGS:OYST

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$366.5m

Last Updated

2021/08/03 00:46 UTC

Data Sources

Company Financials +

Executive Summary

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Oyster Point Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OYST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: OYST's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-13.4%

OYST

-1.2%

US Biotechs

-0.4%

US Market


1 Year Return

-39.3%

OYST

24.5%

US Biotechs

35.9%

US Market

Return vs Industry: OYST underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: OYST underperformed the US Market which returned 35.9% over the past year.


Shareholder returns

OYSTIndustryMarket
7 Day-13.4%-1.2%-0.4%
30 Day-16.3%-0.7%-0.3%
90 Day-28.1%2.0%3.1%
1 Year-39.3%-39.3%26.3%24.5%38.0%35.9%
3 Yearn/a23.0%16.9%62.9%52.7%
5 Yearn/a41.9%30.8%121.3%96.9%

Long-Term Price Volatility Vs. Market

How volatile is Oyster Point Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oyster Point Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OYST ($14.11) is trading below our estimate of fair value ($293.65)

Significantly Below Fair Value: OYST is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OYST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OYST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OYST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OYST is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Oyster Point Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

52.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OYST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OYST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OYST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OYST's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if OYST's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OYST is forecast to be unprofitable in 3 years.


Past Performance

How has Oyster Point Pharma performed over the past 5 years?

-49.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OYST is currently unprofitable.

Growing Profit Margin: OYST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OYST is unprofitable, and losses have increased over the past 5 years at a rate of 49.8% per year.

Accelerating Growth: Unable to compare OYST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OYST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).


Return on Equity

High ROE: OYST has a negative Return on Equity (-42.73%), as it is currently unprofitable.


Financial Health

How is Oyster Point Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: OYST's short term assets ($182.6M) exceed its short term liabilities ($13.7M).

Long Term Liabilities: OYST's short term assets ($182.6M) exceed its long term liabilities ($388.0K).


Debt to Equity History and Analysis

Debt Level: OYST is debt free.

Reducing Debt: OYST had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OYST has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OYST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Oyster Point Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OYST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OYST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OYST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OYST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OYST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Jeff Nau (46 yo)

3.83yrs

Tenure

US$5,752,911

Compensation

Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD5.75M) is above average for companies of similar size in the US market ($USD1.72M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OYST's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: OYST's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oyster Point Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oyster Point Pharma, Inc.
  • Ticker: OYST
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$366.546m
  • Shares outstanding: 25.98m
  • Website: https://www.oysterpointrx.com

Number of Employees


Location

  • Oyster Point Pharma, Inc.
  • 202 Carnegie Center
  • Suite 109
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings


Biography

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the Unite...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 00:46
End of Day Share Price2021/08/02 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.